Skip to content

Exagen Inc. XGN Change in Deferred Revenue

Change in Deferred Revenue at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
-$32.1M-261%
Biodesix, Inc. logo
Biodesix, Inc.BDSX
-$766K-1,023%
Janux Therapeutics logo
Janux TherapeuticsJANX
$46.27M
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$1.08M-75.1%

Other financials

Income statement

See full
Revenue$17.3M+11.7%
Gross profit$10.2M+11.9%
Operating income-$3.4M-1.5%
Net income-$4.0M-5.7%
EPS (diluted)-$0.17+15.0%

Balance sheet

See full
Cash & equivalents$21.7M+90.6%
Total debt$27.1M+15.8%
Total equity$14.4M+125%
Total assets$52.0M+28.9%

Cash flow

See full
Operating cash flow-$10.4M+2.4%
CapEx$228.0K+102%
Free cash flow-$10.6M+1.3%

Valuation

See full
Market cap$112.34M-26.5%
Enterprise value$117.78M-20.3%
P/S1.6×-1.0×

Profitability

See full
Gross margin58.3%-1.0pp
Operating margin-20.6%-2.9pp
Net margin-29.5%+2.5pp
FCF margin-27.5%

Returns & leverage

See full
Return on equity-193.6%+355pp
Debt / equity1.9×-1.8×
Current ratio3.5×+1.1×

Where this comes from

Reported directly by Exagen Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: Exagen Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exagen Inc.'s change in deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exagen Inc.'s change in deferred revenue?
Exagen Inc. (XGN) reported change in deferred revenue of $6K in Q1 2026.
How has Exagen Inc.'s change in deferred revenue changed year-over-year?
Exagen Inc.'s change in deferred revenue decreased by 95.8% year-over-year, from $143K to $6K.
What does change in deferred revenue mean?
Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.